APP and cancer: The general tumor-educated platelet-targets and FDA-approved drugs targeting them and involved in hemostasis and cytoskeletal signaling are expected to hold for cancers in general, while the more NSCLC TEP-specific ones (e.g., FLNA and APP) could be more NSCLC-specific, for instance, not featuring in TEPs from pancreatic cancer [82].